Check out which companies are making headlines before the bell:
DSW—The shoe retailer beat estimates by 7 cents with adjusted quarterly profit of 35 cents per share, with sales easily beating estimates. DSW saw comparable store sales rise 7.6 percent, and it also raised its quarterly dividend to 20 cents per share from 18¾ cents per share.
Burlington Stores—The apparel and accessories retailer reported adjusted quarterly profit of $1.43 per share, 11 cents above estimates, with revenue also exceeding forecasts. Burlington saw comparable store sales rise 6.7 percent from a year earlier.
Alibaba—Stifel Nicolaus upgraded the stock to "buy" from "hold" and added it to the Stifel "Select List." Stifel cites long term benefits from improvements to the online retailer's platform, and notes its multiples compare favorably to those of competitor Amazon.com.
Raytheon—The defense contractor is reportedly in talks to buy network security provider Websense, according to Bloomberg. Websense is currently owned by private equity firm Vista Equity Partners, which Bloomberg said has hired Citigroup to sell Websense for more than $1 billion.
Apple—The company is in talks to launch an online TV service, according to The Wall Street Journal.
Walt Disney—Disney is in talks to invest in fantasy sports site Draft Kings, according to Fortune.
Weight Watchers—The weight-loss firm was downgraded to "underperform" from "neutral" at Credit Suisse, which cites Weight Watchers' earnings outlook as well as its current valuation.
Actavis—The drug maker has been reinstated to the "conviction buy" list at Goldman Sachs, ahead of the completion of its deal to buy Allergan. Goldman said the company's strong generic drug pipeline will be made even stronger by the Allergan deal.
General Motors—Morgan Stanley resumed coverage of GM with an "underweight" rating, saying the automaker's move to return more capital to shareholders may be at odds with its long-term prospects.
Gilead Sciences—A study in the Annals of Internal Medicine concludes that new hepatitis C drugs that shorten treatment times are cost-effective despite their large price tags. Gilead's Sovaldi is one of the more popular of these drugs, and it came under heavy criticism last year for its initial $84,000 price tag.